Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
Innate immune cells are an important part of the body's innate immune system, the first line
of defense against infection and cancer. Tumor killer cells (TKC) are mixed cultures of two
kinds of innate immune cells, namely natural killer cells (NK cells) and gamma delta T cells
(γδT cells), which are co-activated and co-cultured ex-vivo in a certain proportion by the
unique TKC technology. Adoptive TKC transfer is expected to exert a strong anti-tumor effect
through synergistic action between NK cells and γδT cells. In this study, the safety,
tolerance, and preliminary efficacy of adoptive TKC transfer combined with chemotherapy will
be examined in patients with advanced NSCLC.